Dr. Sarah Yim U.S. Food and Drug Administration, USA

Sarah Yim, M.D. is the Director of the Office of Therapeutic Biologics and Biosimilars, in CDER’s Office of New Drugs (OND), since 2019. She has been with FDA since 2005, including 2 years as Director of the Division of Clinical Review in the Office of Generic Drugs, and 11 years... read morein rheumatology regulatory review.

She received her undergraduate degree from Stanford University, Doctor of Medicine degree from the Uniformed Services University of Health Sciences and completed a postdoctoral fellowship in rheumatology at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), at the National Institutes of Health.